Mandar Paradkar, MBBS, DCH, MPH

CRS:

BJMC

Role:

InvestigatorsClinical

Position:

Study Coordinator

Dr. Paradkar is Study Coordinator at the Byramjee Jeejeebhoy Government Medical College Clinical Research Site (BJGMC-CRS) in Pune, India. He coordinates Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPh), and upcoming pediatric TB studies: SHINE and TBM Kids trial. He is a pediatrician by training and successfully completed the full time Master of Public Health degree through Cardiff University, UK, under the prestigious Commonwealth Scholarship Program in November, 2015. He rejoined the site in role of study coordinator December 2015.

In his current role, he coordinates the study activities for adult and pediatric TB study teams at the site. These activities involve regulatory documentation and reporting to the regulatory bodies at the site, recruitment of participants, ensuring the conduct of study procedures are in accordance with the study protocol, staff training, QC procedures, and regular communication with the CRS leadership, study laboratories, BJMC faculty, local authorities for National TB control programme (RNTCP) and the protocol team on relevant subjects. His research interests are clinical epidemiology of pediatric TB and HIV-TB coinfection and aims for research and publications in this subject area.

He completed his medical education in 2007 followed by pediatric post-graduation in 2009, and he worked as a pediatric intensive care registrar at Deenanath Mangeshkar Hospital, a tertiary care hospital in Pune, for a short tenure. He then joined the BJMC-CRS in 2011 and worked for four years as a pediatric research clinician for various HIV studies, including the PROMISE study under NIH’s IMPAACT trial network. He also assisted in adult cryptococcal meningitis study under NIH’s ACTG trial network.

Dr. Paradkar was selected as the New Investigator awardee for year 2011-12 by the IMPAACT network and received mentorship during the award year by Dr. Charles Mitchel (US based IMPAACT investigator). This award included participation on a network protocol development team (Dose finding, safety, and tolerance study of Raltegravir containing antiretroviral therapy in children), participation on the IMPAACT HIV complications scientific committee, and a grant award for research or training purposes. Dr. Paradkar completed the Clinical Vaccine Trials and Good Clinical Practice certificate course from Johns Hopkins University, attended the annual IMPAACT network meetings in Washington, DC, in 2011 and 2012.

  • Member, ACTG TB Meningitis Working Group (Oct 2017)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More